JAK/STAT通路抑制剂已被应用于多种疾病的临床试验，但其全身性用药对机体组织细胞功能活性的影响目前尚不明确.本研究运用基于核磁共振氢谱（1H NMR）的代谢组学方法分析了JAK/STAT通路抑制剂WP1066（20 mg/kg.bw，2天一次，持续2周）对C57BL/6小鼠血清代谢组的影响.首先采用1H NMR技术检测了WP1066处理组和对照组小鼠血清的代谢物，然后对所得的图谱数据进行了主成分分析（PCA）以及正交偏最小二乘法分析（OPLS）.研究结果表明，抑制JAK/STAT通路可明显下调小鼠血清中的N-甲基烟酰胺（N-methylnicotinamide）水平，而上调顺乌头酸（cis-aconitate）、草酰乙酸（oxaloacetate）和乙酰胺（acetamide）水平，这些代谢物改变均与能量代谢密切相关.该结果提示代谢失衡相关指标可能作为JAK/STAT通路抑制剂治疗的临床监测参考指标.
赵欣
,
肖雄杰
,
高东莉
,
张先荣
. JAK/STAT通路抑制剂对C57BL/6小鼠血清代谢组影响的1H NMR研究[J]. 波谱学杂志, 2018
, 35(2)
: 198
-203
.
DOI: 10.11938/cjmr20182630
JAK/STAT pathway inhibitor has been used in clinic trial for several diseases. However, the adverse effect of systematic administration of JAK/STAT pathway inhibitors on cellular function is largely unknown. In the present study, alteration of metabolites in C57BL/6 mice serum were characterized using metabonomic analysis after WP1066 (a JAK/STAT pathway inhibitor) treatment (20 mg/kg.bw, once every 2 days for 2 weeks). 1H NMR spectroscopy was used to detect the effect of WP1066 on metabolites component, and the metabolite profile were analyzed by principle component analysis (PCA) and orthogonal partial least squares (OPLS) analysis. Results showed that the level of N-methylnicotinamide was significantly downregulated, while cis-aconitate, oxaloacetate and acetamide were significantly upregulated in mice serum in response to JAK/STAT pathway inhibition. The above metabolic changes are associated with alterations in energy metabolism, indicating that parameters associated with metabolism unbalance may be used for monitoring the efficiency and adverse effect of JAK/STAT pathway inhibitor.
[1] VILLARINO A V, KANNO Y, O'SHEA J J. Mechanisms and consequences of JAK-STAT signaling in the immune system[J]. Nat Immunol, 2017, 18(4):374-384.
[2] DODINGTON D W, DESAI H R, WOO M. JAK/STAT-Emerging players in metabolism[J]. Trends Endocrinol Metab, 2018, 29(1):55-65.
[3] O'SHEA J J, PLENGE R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease[J]. Immunity, 2012, 36(4):542-550.
[4] MOH A, ZHANG W, YU S, et al. STAT3 sensitizes insulin signaling by negatively regulating glycogen synthase kinase -3 beta[J]. Diabetes, 2008, 57(5):1227-1235.
[5] CORBIT K C, CAMPOREZ J P, TRAN J L, et al. Adipocyte JAK2 mediates growth hormone-induced hepatic insulin resistance[J]. JCI Insight, 2017, 2(3):e91001.
[6] CERNKOVICH E R, DENG J, BOND M C, et al. Adipose-specific disruption of signal transducer and activator of transcription 3 increases body weight and adiposity[J]. Endocrinology, 2008, 149(4):1581-1590.
[7] KALENECKER D, MUELLER K M, BENEDIKT P, et al. Adipocyte STAT5 deficiency promotes adiposity and impairs lipid mobilisation in mice[J]. Diabetologia, 2017, 60(2):296-305.
[8] LEE E B, FLEISCHMANN R, HALL S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis[J]. N Engl J Med, 2014, 370(25):2377-2386.
[9] WINTHROP K. The emerging safety profile of JAK inhibitors in rheumatic disease[J]. Nat Rev Rheumatol, 2017, 13(5):320.
[10] NICHOLSON J K, WILSON I D. Opinion:understanding ‘global’ systems biology:metabonomics and the continuum of metabolism[J]. Nat Rev Drug Discov, 2003, 2(8):668-676.
[11] REAGAN-SHAW S, NIHAL M, AHMAD N. Dose translation from anima to human studies revisited[J]. FASEB J, 2008, 22(3):659-661.
[12] KONG L Y, ABOU-GHAZAL M K, WEI J, et al. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells[J]. Clin Cancer Res, 2008, 14(18):5759-5768.
[13] CRAIG A, CLOARCO O, HOLMES E, et al. Scaling and normalization effects in NMR spectroscopic metabonomic data sets[J]. Anal Ch em, 2006, 78(7):2262-267.
[14] GOVINDARAJU V, YOUNG K, MAUDSLEY A A. Proton NMR chemical shifts and coupling constants for brain metabolites[J]. NMR Biomed, 2000, 13(3):129-153.
[15] MAGNI G, AMICI A, EMANUELLI M, et al. Enzymology of NAD+ homeostasis in man[J]. Cell Mol Life Sci, 2004, 61(1):19-34.
[16] PRZYGODZKI T, KAZMIERCZAK P, SIKORA J, et al. 1-methylnicotinamide effects on the selected markers of endothelial function, inflammation and haemostasis in diabetic rats[J]. Eur J Pharmacol, 2010, 640(1-3):157-162.
[17] MATEUSZUK L, JASZTAL A, MASLAK E, et al. Anti-atherosclerotic effects of 1-methylnicotinamide in Apolipoprotein E/Low-Density Lipoprotein Receptor-Deficient mice:a comparison with nicotinic acid[J]. J Pharmacol Exp Ther, 2016, 356(2):514-524.
[18] STRÖM K, MORALES-ALAMO D, OTTOSSON F, et al. N1-methylnicotinamide is a signalling molecule produced in skeletal muscle coordinating energy metabolism[J]. Sci Rep, 2018, 8(1):3016.
[19] VAN DER BLIEK A M, SEDENSKY M M, MORGAN P G. Cell Biology of the Mitochondrion[J]. Genetics, 2017, 207(3):843-871.
[20] DELAVAL E, PERICHON M, FRIGUET B. Age-related impairment of mitochondrial matrix aconitase and ATP-stimulated protease in rat liver and heart[J]. Eur J Biochem, 2004, 271(22):4559-4564.
